Cogent Biosciences (COGT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual Meeting scheduled for June 9, 2026, with voting open until June 8, 2026, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies before May 26, 2026.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of three Class II director nominees to serve until the 2029 Annual Meeting.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
Advisory vote on executive compensation for named executive officers.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Nominees for Class II directors: Dr. Chris Cain, Arlene M. Morris, and Todd Shegog.
Directors to serve until 2029 or until successors are elected and qualified.
Latest events from Cogent Biosciences
- Three NDAs pending FDA review, strong trial results, and cash runway into late 2028.COGT
Q2 2026 - Pivotal trial readouts for bezuclastinib in rare diseases and GIST expected in 2025.COGT
Guggenheim SMID Cap Biotech Conference - All proposals, including director elections and auditor ratification, were approved.COGT
AGM 2026 - Bezuclastinib plus sunitinib delivers breakthrough efficacy in GIST, with rapid adoption anticipated.COGT
Jefferies Global Healthcare Conference 2026 - Q1 2026 net loss rose to $97.4M; $866.4M cash funds dual launches and operations into 2028.COGT
Q1 2026 - Director elections, auditor ratification, and executive pay are key votes amid major clinical and financial progress.COGT
Proxy filing - Bezuclastinib's pivotal trial wins set up a transformative 2026 launch and long-term market leadership.COGT
44th Annual J.P. Morgan Healthcare Conference - Bezuclastinib delivered robust symptom and biomarker improvements with good tolerability in non-advanced SM.COGT
Study Result - Pivotal trial readouts for Bezuclastinib in SM and GIST expected in 2025, with strong market potential.COGT
Piper Sandler 36th Annual Healthcare Conference